Author

E. Riviere

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Assay:proteomics· 2 Approach:Bayesian inference· 1 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

A. van Rie· 2 shared A. Brignier· 1 shared A. Maria· 1 shared A. Ouedrani· 1 shared A. Sokal· 1 shared A. Vandenberghe· 1 shared A.-F. Collange· 1 shared B. Cuypers· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. van Rie

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Predicting MmpR-based bedaquiline resistance using sequence- and structure-based features

E. Riviere, M. Safarpour, P. Meysman, B. Cuypers, C. Meehan, K. Laukens, A. van Rie

This paper develops a machine learning model to predict bedaquiline resistance using sequence and structural features of Rv0678 variants, achieving moderate performance but not sufficient for clinical use.

bioRxiv · Dec 19, 2022 · PreprintMicrobiology

A Bayesian approach to estimate the probability of resistance to bedaquiline in the presence of a genomic variant

D. Z. Anlay, E. Riviere, P. H. T. Tu, S. Abrams, A. Van Rie

The paper uses Bayesian methods to estimate bedaquiline resistance probabilities based on genomic variants and expert opinions, finding varying probabilities across mutation types.

bioRxiv · Aug 30, 2022Microbiology

Absence of severe COVID-19 in patients with clonal mast cells activation disorders: effective anti-SARS-CoV-2 immune response.

J. Rossignol, A. Ouedrani, C. Bulai-Livideanu, S. Barete, L. Terriou, D. Launay, R. Lemal, C. Greco, L. Frenzel, C. Meni, C. Bodemere-Skandalis, L. Polivka, A.-F. Collange, H. Hachichi, S. Bouzourine, , Mania

The paper investigates the immune response in patients with clonal mast cells activation disorders (cMCADs) during SARS-CoV-2 infection and finds no severe COVID-19 cases and robust anti-viral immunity.

bioRxiv · Sep 1, 2021 · PreprintImmunology

A reservoir of rituximab-resistant splenic memory B cells contributes to relapses after B-cell depletion therapy

E. Crickx, P. Chappert, S. Weller, A. Sokal, I. Azzaoui, A. Vandenberghe, G. Bonnard, G. Rossi, T. Fadeev, S. Storck, L. Galicier, V. Meignin, E. Riviere, B. Godeau, M. Michel, , M. Mahevas

bioRxiv · Nov 7, 2019 · PreprintImmunology